Premium
Revance Therapeutics Inc (RVNC)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD pl... Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products. Show more
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class Action - RVNC PR Newswire NEW YORK, Feb. 3, 2025 NEW YORK, Feb. 3, 2025...
Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline PR Newswire JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Jan. 31, 2025 Crown offer of...
The Gross Law Firm Reminds Revance Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC PR Newswire NEW YORK, Jan. 30, 2025 NEW...
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire NEW YORK, Jan. 27, 2025 NEW YORK, Jan. 27, 2025...
Shareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC PR Newswire NEW YORK, Jan. 23, 2025 NEW YORK, Jan. 23, 2025...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.03 | -0.821917808219 | 3.65 | 3.67 | 3.615 | 3138291 | 3.63119179 | CS |
| 4 | 0.11 | 3.1339031339 | 3.51 | 3.7 | 3.23 | 3677043 | 3.54316474 | CS |
| 12 | -0.155 | -4.1059602649 | 3.775 | 4.365 | 3.01 | 3085815 | 3.43454115 | CS |
| 26 | 0.83 | 29.7491039427 | 2.79 | 6.65 | 2.755 | 3885607 | 5.12179725 | CS |
| 52 | -1.62 | -30.9160305344 | 5.24 | 7.56 | 2.3 | 2891434 | 4.79331245 | CS |
| 156 | -9.11 | -71.5632364493 | 12.73 | 37.98 | 2.3 | 1851617 | 12.22762592 | CS |
| 260 | -19.17 | -84.1158402808 | 22.79 | 37.98 | 2.3 | 1363609 | 14.16591044 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
